ACAD Financials | Key Metrics & Investor Analysis
The financial statements for ACAD (ACAD) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| A Agilent Technologies, Inc. | $119.77 -0.51% |
| SLNO Soleno Therapeutics, Inc. | $52.57 -0.10% |
| ADMA ADMA Biologics, Inc. | $10.65 +1.53% |
| LGND Ligand Pharmaceuticals Incorporated | $225.09 -3.12% |
| CRNX Crinetics Pharmaceuticals, Inc. | $39.77 +0.05% |
| VKTX Viking Therapeutics, Inc. | $35.45 -0.20% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| A Agilent Technologies, Inc. | $119.77 | -0.51% | 33.88 B | 26.44 | 4.53 | 0.84% | Buy | 1.96 |
| SLNO Soleno Therapeutics, Inc. | $52.57 | -0.10% | 2.72 B | 134.79 | 0.39 | 0.00% | Buy | 4.98 |
| ADMA ADMA Biologics, Inc. | $10.65 | +1.53% | 2.54 B | 17.75 | 0.60 | 0.00% | Buy | 4.29 |
| LGND Ligand Pharmaceuticals Incorporated | $225.09 | -3.12% | 4.49 B | 36.72 | 6.13 | 0.00% | Buy | 296 |
| CRNX Crinetics Pharmaceuticals, Inc. | $39.77 | +0.05% | 4.16 B | -8.03 | -4.95 | 0.00% | Buy | 684 |
| VKTX Viking Therapeutics, Inc. | $35.45 | -0.20% | 4.10 B | -11.11 | -3.19 | 0.00% | Buy | 1.66 |
Frequently Asked Questions
What are ACAD's latest financial results?
Review ACAD's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has ACAD's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is ACAD's cash flow situation and liquidity?
Cash flow statements reveal how ACAD generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does ACAD's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether ACAD is outperforming or lagging within its sector.
Are ACAD's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether ACAD's profits are repeatable and supported by strong fundamentals.